Atomi Financial Group Inc. Buys 229 Shares of BioNTech SE (NASDAQ:BNTX)

Atomi Financial Group Inc. raised its position in BioNTech SE (NASDAQ:BNTX) by 6.7% in the 4th quarter, HoldingsChannel reports. The fund owned 3,635 shares of the company’s stock after purchasing an additional 229 shares during the period. Atomi Financial Group Inc.’s holdings in BioNTech were worth $414,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. FMR LLC boosted its position in shares of BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after acquiring an additional 5,598,190 shares in the last quarter. Fred Alger Management LLC acquired a new stake in BioNTech during the third quarter valued at approximately $59,485,000. Point72 Asset Management L.P. grew its stake in shares of BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after purchasing an additional 341,311 shares during the period. Braidwell LP acquired a new position in BioNTech during the third quarter worth $29,425,000. Finally, New York State Common Retirement Fund increased its position in shares of BioNTech by 457.9% during the 3rd quarter. New York State Common Retirement Fund now owns 218,067 shares of the company’s stock worth $25,900,000 after purchasing an additional 178,981 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $118.14 on Friday. The company has a fifty day moving average price of $115.78 and a 200 day moving average price of $105.70. The firm has a market cap of $28.32 billion, a PE ratio of -56.26 and a beta of 0.18. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same period in the prior year, the firm earned $0.73 earnings per share. BioNTech’s revenue for the quarter was up 38.9% compared to the same quarter last year. Research analysts predict that BioNTech SE will post -3.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on BNTX shares. TD Cowen decreased their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research note on Tuesday, November 5th. BMO Capital Markets reissued an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and increased their price objective for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Berenberg Bank initiated coverage on BioNTech in a research note on Tuesday, November 19th. They issued a “buy” rating and a $130.00 target price for the company. Finally, The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the company from $90.00 to $137.00 in a report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.